New combo therapy aims to halt returning prostate cancer

NCT ID NCT02203695

Completed Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug enzalutamide to standard radiation therapy can better control prostate cancer that has come back after surgery. Eighty-six men with rising PSA levels after prostate removal took part. The goal was to see if the combination could delay cancer progression more than radiation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF THE PROSTATE

Contacts and locations

Locations

Indiana University

Lafayette, Indiana, 47904, United States
Karmanos Cancer Center

Detroit, Michigan, 48201, United States
Oregon Health Sciences University

Portland, Oregon, 97239, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Suburban Hospital

Bethesda, Maryland, 20814, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Michigan Health System

Ann Arbor, Michigan, 48109, United States
University of Utah - Huntsman Cancer Center

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.